Results 101 to 110 of about 4,903,971 (217)

Detection of renal tubular transporter proteins in canine urinary extracellular vesicles using liquid chromatography–tandem mass spectrometry

open access: yesVeterinary Clinical Pathology, EarlyView.
Abstract Urinary extracellular vesicles (UEVs) are membranous particles that carry renal tubular transporter proteins. Here, we evaluate whether selected renal tubular transporter proteins can be detected in UEVs isolated from small volume (1–5 mL) canine urine samples of healthy dogs and canine patients with elevated circulating parathyroid hormone ...
L. J. McGravey   +2 more
wiley   +1 more source

Primary Hyperparathyroidism in Pregnancy: Successful Parathyroidectomy during First Trimester

open access: yesCase Reports in Endocrinology, 2018
Primary hyperparathyroidism in pregnancy can result in significant maternal and fetal complications. When indicated, prompt parathyroidectomy in the early second trimester is considered the treatment of choice.
Niranjan Tachamo   +5 more
doaj   +1 more source

Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial [PDF]

open access: yes, 2012
Background Increasing evidence suggests the bidirectional interplay between parathyroid hormone and aldosterone as an important mechanism behind the increased risk of cardiovascular damage and bone disease observed in primary hyperparathyroidism.
A Struthers   +61 more
core   +3 more sources

Molecular pathophysiology of chronic kidney disease–mineral and bone disorder: Focus on the fibroblast growth factor 23–Klotho axis and bone turnover dynamics

open access: yesExperimental Physiology, EarlyView.
Abstract Chronic kidney disease–mineral and bone disorder (CKD‐MBD) is a major complication of chronic kidney disease (CKD), characterized by disruptions in mineral metabolism, abnormal bone turnover and vascular calcification, which collectively increase the risk of fractures and cardiovascular disease.
Alief Waitupu   +4 more
wiley   +1 more source

Primary Hyperparathyroidism: lessons from two cases

open access: yesAtti della Accademia Peloritana dei Pericolanti - Classe di Scienze Medico-Biologiche, 2019
Primary hyperparathyroidism (PHPT) is the most common cause of  hypercalcemia and is characterized by hypercalcemia and levels of parathyroid hormone (PTH) that are inappropriately high for the hypercalcemic state.
Giuseppe Turiano, Astrid Herberg
doaj   +1 more source

Hyperparathyroidism and hyperfunctioning supernumary glands : considerations for challenging management [abstract] [PDF]

open access: yes, 2010
Hyperparathyroidism can be treated surgically with high success rates. While the majority of patients have four glands, the presence of a supernumerary gland may be encountered as a normal anatomic variant in up to 13% of the population.
Page, Matthew, Showmaker, Jason
core  

Urinary Calcium Measurement in Patients With Hypercalcaemia; Endocrine Physicians and Surgeons Survey Results From UK

open access: yesClinical Endocrinology, Volume 103, Issue 5, Page 757-760, November 2025.
ABSTRACT Background In patients with hypercalcaemia, assessment of urinary calcium excretion helps differentiate primary hyperparathyroidism (PHPT) from familial hypocalciuric hypercalcaemia (FHH). For this, 24 h calcium to creatinine clearance ratio (CCCR) is recommended, but others tests like random CCCR, 24 h urine calcium excretion (UCE), and ...
Muhammad Fahad Arshad   +1 more
wiley   +1 more source

Prevalence of Metabolic Syndrome in Primary Hyperparathyroidism

open access: yesHaseki Tıp Bülteni, 2017
Aim: In this study, we aimed to evaluate the prevalence of metabolic syndrome (MetS), metabolic abnormalities and independent predictors of MetS in primary hyperparathyroidism and to contribute to long-term follow-up and management of these patients ...
Gökçen Tuğba Çevik   +7 more
doaj   +1 more source

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis [PDF]

open access: yes, 2019
Background: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast
Block, Geoffrey A.   +9 more
core   +1 more source

Cardiovascular Morbidity in Patients Undergoing Successful Surgery for Primary Hyperparathyroidism

open access: yesClinical Endocrinology, Volume 103, Issue 5, Page 669-681, November 2025.
ABSTRACT Objective Although previous studies have shown reduced cardiovascular events following parathyroidectomy (PTX), it is unclear whether this extends to contemporary patients diagnosed and treated with milder disease than previously. The aim of this nation‐wide study was to determine the effect on cardiovascular events after PTX, and to ...
Martin Nilsson   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy